Search company, investor...

Pharma Surgics


Other Investors | Alive

About Pharma Surgics

PharmaSurgics develops and commercialises a treatment for the prevention of harmful scarring (adhesions)

Headquarters Location


Missing: Pharma Surgics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Pharma Surgics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Pharma Surgics Frequently Asked Questions (FAQ)

  • What is Pharma Surgics's latest funding round?

    Pharma Surgics's latest funding round is Other Investors.

  • Who are the investors of Pharma Surgics?

    Investors of Pharma Surgics include CSE Holding, Midroc Invest and Karolinska Development.

  • Who are Pharma Surgics's competitors?

    Competitors of Pharma Surgics include Reata Pharmaceuticals, Immune Targeting Systems, Santarus, Okairos, IASO Pharma and 12 more.

Compare Pharma Surgics to Competitors


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.


Photopharmica, developing light sensitive drugs for the prevention and treatment of diseases in the anti-infective and oncology markets photosensitisers, for industrial applications

Cardeon Corporation

Cardeon Corporation is engaged in developing solutions for stroke prevention


MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the treatment of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of dermatological diseases (end of Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada.


MucoVax is specialised in the development and production of milk based antibody therapies for the prevention and dietary management of gastro-intestinal infections in humans as well as in animals.

Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.